Please Note: Blog posts are not selected, edited or screened by Seeking Alpha editors.

New This Week On Slingshot Insights SA Premium Service: 8/6/18

|About: Biofrontera (BFRA), GBT

Summary

This week's Marketplace postings include interviews with experts discussing assets from: GBT, ONCO, B8F.F.

This series of instablog posts will highlight the most recently executed transcripts being added to the “Become the Smart Money” , Slingshot Insights Seeking Alpha Premium service. In these blog posts we will give you a bit more information about the subject matter experts we interviewed, the topics covered, and relevant companies. We hope that these brief overviews, combined with our free content and articles, will display what we believe is the content’s unique value to our members. Please don’t hesitate to directly ask us questions at any time via SeekingAlpha Direct message or email to info@slingshotinsights.com.

Why Do Expert Research?

While many individuals we speak to are unaware of the role expert interviews play for many professional investors, it is a $600mm industry. Many funds pay in excess of $100,000 a year just for a relationship with an expert network and over a thousand dollars per call. While these numbers sound staggering, many investors consider them well worth the money. Slingshot Insights’ sharing model has transformed the price of these calls for our customers and now we are making them even more affordable to you on the SeekingAlpha Marketplace for only $75 per month.

Become the newest subscriber to “Become the Smart Money” here and gain access to all of these : Link

Transcript 1: A 3rd View: Discussing GBT's recent Sickle Cell Phase 3 HOPE Results for Voxelotor (Previously GBT440)

Ticker: GBT

Call Date: 7/2/18

Who's the Expert?

  • Assistant Professor in Medicine and Pediatrics and Director of Clinical Research in Benign Hematology.
  • Manages 350 out of the 900 patients with sickle cell disease at Duke University and 10 patients with beta thalassemia.
  • Director of Duke’s sickle cell transition program where he has led multiple trials in sickle cell disease and is 75% research focused.

Interview Goal:

This conversation will discuss the publicly released Phase 3 results from the HOPE study released June 27th, 2018. The conversation will dig into the primary and secondary endpoints, likelihood of FDA approval and role the treatment might play in the market.

Link to original project page on Slingshot Insights with questions asked: link

Transcript 2: Exploring the market potential of Oncopeptides' melflufen (Ygalo) in treating multiple myeloma

Ticker: ONCO.ST

Call Date: 7/2/18

Who's The Expert?

  • Director of the Stem Cell Transplant Program and the Clinical Program Director of Hematologic Malignancies at Montefiore Medical Center; fellowship trained at MD Anderson.
  • Currently treats 200 patients with multiple myeloma.
  • Research focuses on the treatment of acute leukemias, lymphoma and multiple myeloma, especially using stem cell transplant as a platform for immunotherapy to treat these disorders.

Interview Goal:

To get a better understanding for the treatment of multiple myeloma and where Ygalo could fit into the landscape.

Link to original project page on Slingshot Insights with questions asked: link

Transcript 3: Evaluating BioFrontera's pipeline in treating actinic keratosis and superficial basal cell carcinoma

Ticker: BFRA

Call Date: 7/3/18

Who's the Expert?

  • Clinical dermatologist and Special adviser oncology of the professional association of German dermatologists.
  • Currently manages 4,200 patients in a 3 month period (650 with actinic keratosis and 110 with basal cell carcinoma and uses the BF-RhodoLED lamp.
  • Board Member Germany European Academy of Dermatology and Venereology.

Interview Goal:

To get an expert's view on Biofrontera's Ameluz (aminolevulinic acid hydrochloride gel) as well as other photodynamic therapies currently in development.

Link to original project page on Slingshot Insights with questions asked: link

Disclosure: I/we have no positions in any stocks mentioned, and no plans to initiate any positions within the next 72 hours.